Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Zhelev

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Journal of Biomechanical Engineering|May 1, 1994
Numerical simulation of the flow of highly viscous drops down a tapered tubeR Tran-Son-Tay, T F Kirk, D V Zhelev, et al.
Applied and Environmental Microbiology|October 9, 2012
Effect of the Bacillus atrophaeus subsp. globigii Spo0F H101R mutation on strain fitnessDoncho V Zhelev, Mia Hunt, Anna Le, et al.
The Journal of Biological Chemistry|December 22, 1999
Chemoattractant receptors activate distinct pathways for chemotaxis and secretion. Role of G-protein usageB Haribabu, D V Zhelev, B C Pridgen, et al.
Molecular Cancer Therapeutics|September 1, 2021
Antibody-Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody InternalizationSamantha Buongervino, Maria V Lane, Emily Garrigan, et al.
Immunologic Research|May 8, 2001
Function and regulation of chemoattractant receptorsB Haribabu, R M Richardson, M W Verghese, et al.
Biochemistry|July 11, 1995
Experimental tests for protrusion and undulation pressures in phospholipid bilayersT J McIntosh, S Advani, R E Burton, et al.
Frontiers in Oncology|March 16, 2023
Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugatesYe-Jin Kim, Wei Li, Doncho V Zhelev, et al.
Biochimica Et Biophysica Acta|November 7, 1993
Electrical properties of cell pellets and cell electrofusion in a centrifugeI G Abidor, A I Barbul, D V Zhelev, et al.
Journal for Immunotherapy of Cancer|December 2, 2022
GPC2 antibody-drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapiesGuillem Pascual-Pasto, Brendan McIntyre, Rawan Shraim, et al.
Cell Reports. Medicine|August 2, 2021
A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitopeSwetha Raman, Samantha N Buongervino, Maria V Lane, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Journal of Biomechanical Engineering|May 1, 1994
Numerical simulation of the flow of highly viscous drops down a tapered tubeR Tran-Son-Tay, T F Kirk, D V Zhelev, et al.
Applied and Environmental Microbiology|October 9, 2012
Effect of the Bacillus atrophaeus subsp. globigii Spo0F H101R mutation on strain fitnessDoncho V Zhelev, Mia Hunt, Anna Le, et al.
The Journal of Biological Chemistry|December 22, 1999
Chemoattractant receptors activate distinct pathways for chemotaxis and secretion. Role of G-protein usageB Haribabu, D V Zhelev, B C Pridgen, et al.
Molecular Cancer Therapeutics|September 1, 2021
Antibody-Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody InternalizationSamantha Buongervino, Maria V Lane, Emily Garrigan, et al.
Immunologic Research|May 8, 2001
Function and regulation of chemoattractant receptorsB Haribabu, R M Richardson, M W Verghese, et al.
Biochemistry|July 11, 1995
Experimental tests for protrusion and undulation pressures in phospholipid bilayersT J McIntosh, S Advani, R E Burton, et al.
Frontiers in Oncology|March 16, 2023
Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugatesYe-Jin Kim, Wei Li, Doncho V Zhelev, et al.
Biochimica Et Biophysica Acta|November 7, 1993
Electrical properties of cell pellets and cell electrofusion in a centrifugeI G Abidor, A I Barbul, D V Zhelev, et al.
Journal for Immunotherapy of Cancer|December 2, 2022
GPC2 antibody-drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapiesGuillem Pascual-Pasto, Brendan McIntyre, Rawan Shraim, et al.
Cell Reports. Medicine|August 2, 2021
A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitopeSwetha Raman, Samantha N Buongervino, Maria V Lane, et al.
Pageof 5